Neurofilament light chain levels correlate with clinical measures in CLN3 disease

Purpose CLN3 disease is a neurodegenerative disorder with onset in childhood. It affects multiple functions at different developmental stages. Incomplete understanding of the pathophysiology hampers identification of cell and tissue biochemical compounds reflective of the disease process. As treatment approaches are being explored, more sensitive, objective, quantifiable, and clinically relevant biomarkers are needed. Methods We collected prospective biosamples from 21 phenotyped individuals with CLN3. We measured neurofilament light chain (NEFL) levels, a marker of neuronal damage, in cross-sectional CSF and serum samples from individuals with CLN3 and in pediatric non-CLN3 controls using two different assays. Results Cerebrospinal fluid (CSF) and serum NEFL levels are significantly higher in CLN3 (CSF: 2096 +/- 1202; serum: 29.0 +/- 18.0 pg/mL) versus similarly aged non-CLN3 (CSF: 345 +/- 610; serum: 6.7 +/- 3.2 pg/mL) samples. NEFL levels correlate with Unified Batten Disease Rating Scale and adaptive behavior composite scores, and magnetic resonance (MR) spectroscopy markers. NEFL levels from CSF and serum are strongly correlated (r(p) = 0.83; p < 0.0001). Conclusion CSF and serum NEFL levels increase in multiple neurologic conditions. Here, we show that CSF and serum NEFL levels also increase in CLN3 (versus non-CLN3) and correlate with other disease-relevant measures. These findings suggest NEFL as a relevant and feasible biomarker for applications in CLN3 clinical trials and management.

Automated summary

CLN3 disease is a neurodegenerative disorder with onset in childhood, and the levels of NEFL in CSF and serum have been found to increase in CLN3 individuals compared to non-CLN3 controls. These findings suggest NEFL as a relevant biomarker for CLN3 clinical trials and management.